Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: A potential diagnostic pitfall

Histopathology

Volumn 47, Issue 1, 2005, Pages 41-47

  Pauwels, P ^a   Debiec Rychter, M ^b   Stul, M ^b   De Wever, I ^c   Van Oosterom, A T ^c   Sciot, Raf ^b,c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

CD117 antigen; CD34 antigen; Desmin; Gastrointestinal stromal tumours; Imatinib mesylate; Kit mutational analysis; Phenotype

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CALRETININ; CD20 ANTIGEN; CD3 ANTIGEN; CD30 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; DESMIN; GENOMIC DNA; IMATINIB; KERATIN; PROTEIN S 100; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CASE REPORT; GASTROINTESTINAL STROMAL TUMOR; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTERSTITIAL CELL OF CAJAL; LIVER METASTASIS; MALE; MITOSIS RATE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR VOLUME;

ACTINS; ADULT; AGED; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; DESMIN; GASTROINTESTINAL STROMAL TUMORS; GASTROINTESTINAL TRACT; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MIDDLE AGED; MUSCLE, SMOOTH; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 22144464484     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2005.02179.x     Document Type: Article

References (15)

1. Fletcher CDM, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum. Pathol. 2002; 33; 459-465.
2. Miettinen M, Lasota J. Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical and molecular genetic features and differential diagnosis. Virchows Arch. 2001; 348; 1-12.
3. Kindblom L-G, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemarker cell tumor (GIPACT). Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am. J. Pathol. 1998; 152; 1259-1269.
4. Sicar K, Hewlett BR, Huizinga JD et al. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am. J. Surg. Pathol. 1999; 23; 377-389.
5. Heinrich MC, Corless CL, Duensing A et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299; 708-710.
6. Rubin BP, Singer S, Tsao C et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001; 61; 8118-8121.
7. Van Oosterom AT, Judson IR, Verweij J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal tumors: a phase I study. Lancet 2001; 358; 1421-1423.
8. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 2002; 347; 472-480.
9. Debiec-Rychter M, Wasag B, Stul M et al. Gastrointestinal stromal tumors (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J. Pathol. 2004; 202; 430-438.
10. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: gastrointestinal stromal tumors. Cancer Genet. Cytogenet. 2002; 135; 1-22.
11. Medeiros F, Corless CL, Duensing A et al. KIT-negative gastrointestinal stromal tumors. Am. J. Surg. Pathol. 2004; 28; 889-894.
12. Allander SV, Nupponen NN, Ringer M et al. Gastrointestinal stromal tumors with KIT mutation exhibit a remarkably homogenous gene expression profile. Cancer Res. 2001; 61; 8264-8268.
13. Miettinen M, Monihan JM, Sarloma-Rikala M et al. Gastrointestinal stromal tumors/smooth muscle tumors/GISTs in the omentum and mesentery: clinicpathologic and immunohistochemical study of 26 cases. Am. J. Surg. Pathol. 1999; 23; 1109-1119.
14. Torihahsi S, Nishi K, Tokutomi Y et al. Blockade of Kit signaling induces transdifferentiation of interstitial cells of Cajal to smooth muscle phenotype. Gastroenterology 1999; 117; 140-148.
15. Fletcher JA, Corless CL, Dimitrijevic S et al. Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumors (GIST). Proc. ASCO 2003; 22; 815 (abstract 3275).